Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EP300 | Q09472 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | HPGD | P15428 | 4/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | CETP | P11597 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | SOAT1 | P35610 | 2/20 | 0.42 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.41 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5349681 | 0.82 | HRH3 (0.39) | TOP2AMEN1PKMKMT2A | |
| SCHEMBL5357183 | 0.78 | ALDH1A1 (0.46) | ALDH1A1HPGDLMNAHDAC3HDAC1 | |
| Hydrochloric Acid SCHEMBL1895255 | 0.78 | ALDH1A1 (0.42) | EP300ALDH1A1KDM4EHPGDGAA | |
| SCHEMBL6500635 | 0.76 | EP300 (0.57) | EP300ALDH1A1KDM4EHPGDGAA | |
| SCHEMBL24604572 | 0.75 | ALDH1A1 (0.46) | EP300ALDH1A1KDM4EHPGDGAA | |
| SCHEMBL26981100 | 0.74 | HPGD (0.47) | EP300ALDH1A1KDM4EHPGDGAA | |
| SCHEMBL4308968 | 0.74 | MEN1 (0.45) | ALDH1A1KDM4EHSD17B10TSHRMAPK1 | |
| SCHEMBL6411140 | 0.74 | HRH3 (0.46) | LMNASMN1; SMN2S1PR2NPSR1SLC2A1 | |
| SCHEMBL26981080 | 0.72 | ALDH1A1 (0.48) | EP300ALDH1A1KDM4EHPGDGAA | |
| SCHEMBL26981132 | 0.72 | EGFR (0.47) | ALDH1A1KDM4EHPGDGAAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7288550-B2 | Thioether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-10-30 | — | — | US | disclosed |
| US-7276515-B2 | Thioether substituted imidazoquinolines | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2007-10-02 | — | — | US | disclosed |
| US-6949649-B2 | Thioether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES CO. (US) | 2005-09-27 | — | — | US | disclosed |
| US-20050209267-A1 | Thioether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2005-09-22 | — | — | US | disclosed |
| US-20050209268-A1 | Thioether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2005-09-22 | — | — | US | disclosed |
| US-6921826-B2 | Thioether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES CO. (US) | 2005-07-26 | — | — | US | disclosed |
| EP-1541572-A1 | Thioether substituted imidazoquinolines | 3M Innovative Properties Company (US) | 2005-06-15 | — | — | EP | disclosed |
| EP-1341791-B1 | THIOETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES CO (US) | 2005-05-25 | — | — | EP | disclosed |
| EP-1451191-A1 | THIOETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M Innovative Properties Company (US) | 2004-09-01 | — | — | EP | disclosed |
| US-20040102471-A1 | Thioether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-05-27 | — | — | US | disclosed |
| US-20040097736-A1 | Thioether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-05-20 | — | — | US | disclosed |
| US-6667312-B2 | Useful as immune response modifiers | 3M INNOVATIVE PROPERTIES COMPANY | 2003-12-23 | — | — | US | disclosed |
| US-6664264-B2 | Thioether substituted imidazoquinoline or tetrahydroimdazoquinoline compounds induce the biosynthesis of cytokines such as interferon and useful for treating viral disease in an animal | 3M INNOVATIVE PROPERTIES COMPANY | 2003-12-16 | — | — | US | disclosed |
| EP-1341791-A2 | THIOETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M Innovative Properties Company (US) | 2003-09-10 | — | — | EP | disclosed |
| WO-2003050121-A1 | THIOETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2003-06-19 | — | — | WO | disclosed |
| US-20030100764-A1 | Thioether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-05-29 | — | — | US | disclosed |
| US-20020173655-A1 | Thioether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2002-11-21 | — | — | US | disclosed |
| WO-2002046192-A2 | THIOETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209267-A1 | Thioether substituted imidazoquinolines | IFNG, IRF3, IL2 | EP300 2093/4885ALDH1A1 2256/4885KDM4E 1675/4885 |
| US-20050209268-A1 | Thioether substituted imidazoquinolines | IFNG, IRF3, IL2 | EP300 2093/4885ALDH1A1 2256/4885KDM4E 1675/4885 |
| US-20040097736-A1 | Thioether substituted imidazoquinolines | IFNG, IRF3, IL2 | EP300 2093/4885ALDH1A1 2256/4885KDM4E 1675/4885 |
| US-20020173655-A1 | Thioether substituted imidazoquinolines | IFNG, IRF3, IL2 | EP300 2093/4885ALDH1A1 2256/4885KDM4E 1675/4885 |
| US-20040102471-A1 | Thioether substituted imidazoquinolines | IFNG, IRF3, IL2 | EP300 2093/4885ALDH1A1 2256/4885KDM4E 1675/4885 |
| US-20030100764-A1 | Thioether substituted imidazoquinolines | IFNG, IRF3, IL2 | EP300 2093/4885ALDH1A1 2256/4885KDM4E 1675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.